Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL2 | P60568 | 12/20 | 0.56 |
| ▸ | STIM1 | Q13586 | 3/20 | 0.53 |
| ▸ | ORAI1 | Q96D31 | 3/20 | 0.53 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.52 |
| ▸ | TNF | P01375 | 1/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14887333 | 0.89 | STIM1 (0.48) | IL2STIM1ORAI1ORAI2TNF | |
| SCHEMBL14881301 | 0.88 | MEN1 (0.53) | IL2STIM1ORAI1SCN9ANPC1 | |
| SCHEMBL14881425 | 0.88 | STIM1 (0.51) | IL2STIM1ORAI1ORAI2NPC1 | |
| SCHEMBL16017211 | 0.87 | RAB9A (0.50) | STIM1ORAI1NPC1TP53RAB9A | |
| SCHEMBL29505146 | 0.86 | IL2 (0.59) | IL2STIM1ORAI1ORAI2NPC1 | |
| SCHEMBL2596001 | 0.86 | IL2 (0.59) | IL2STIM1ORAI1ORAI2NPC1 | |
| SCHEMBL1701956 | 0.86 | STIM1 (0.66) | IL2STIM1ORAI1ORAI2SCN9A | |
| SCHEMBL14150380 | 0.84 | STIM1 (0.59) | IL2STIM1ORAI1ORAI2NPC1 | |
| SCHEMBL14887561 | 0.84 | STIM1 (0.56) | IL2STIM1ORAI1ORAI2SCN9A | |
| SCHEMBL16017274 | 0.83 | NPC1 (0.50) | IL2STIM1ORAI1ORAI2SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140256771-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. | 2014-09-11 | — | — | US | disclosed |
| US-20140256771-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. | 2014-09-11 | — | — | US | disclosed |
| US-20140256771-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. | 2014-09-11 | — | — | US | disclosed |
| WO-2013059666-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2013-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256771-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | IL2 3716/4885STIM1 17/4885ORAI1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.